Mycosis Fungoides (MF) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Mycosis Fungoides (MF) Emerging Therapy and TPP Insights

Thelansis's "Mycosis Fungoides (MF) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Mycosis Fungoides (MF) Overview

Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, a rare cancer that begins in T-cells but manifests primarily as skin lesions, typically progressing slowly from patches to thicker plaques over an extended period before, in a minority of patients, advancing to more aggressive stages. Because the disease is generally indolent early on, initial management centers on skin-directed therapies such as topical treatments, targeted light-based therapy, and localized radiation, with treatment intensity escalating only as disease stage advances or symptoms become more troublesome. For patients who progress to more advanced or treatment-resistant disease, systemic options have expanded meaningfully in recent years, including targeted antibody-based therapies that home in on specific markers found on the cancerous T-cells, offering better tolerability than traditional chemotherapy for many patients, alongside other immune and cell-directed treatments used for select patient subsets. Durable remission or cure remains difficult to achieve outside of very early, localized disease, and investigation continues into additional targeted therapies for treatment-resistant cases.

Key Highlights

• In Germany, incident Mycosis Fungoides (MF) cases are projected to increase from 525 in 2025 to 552 by 2035.
• MF is the most common form of cutaneous T-cell lymphoma, characterized by a chronic and progressive disease course.
• Delayed diagnosis and limited treatment options for advanced disease remain key clinical challenges.
• Significant unmet need persists for therapies that provide durable responses and improve long-term outcomes.

Market Overview

• The France MF market is projected to grow from $14M in 2025 to $26M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted and biologic therapies
• Growing clinical research in cutaneous T-cell lymphoma
• Future growth will depend on therapies offering durable disease control with improved safety profiles.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Virogen Biotechnology Inc.
• Soligenix
• SciTech Development, Inc.